Trial Profile
Rituxan injection drug use-results survey in ABO-incompatible kidney transplantation recipients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2020
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical; Zenyaku Kogyo
- 03 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 20 Sep 2016 New trial record